Clinical Trial Update: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) [Phase 3]

View source ↗

Summary

This is a Phase 3 long-term follow-up update for long-acting cabotegravir used as HIV PrEP, with the study currently recruiting participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Apretude (cabotegravir long-acting) (cabotegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: RECRUITING